Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 06, 2024 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
February 22, 2024 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics to Present at Upcoming February Investor Conferences
February 01, 2024 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 29, 2024 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
January 24, 2024 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2024 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 07, 2023 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome
November 06, 2023 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...